India
· Delayed Price · Currency is INR Gland Pharma Statistics
Total Valuation
Gland Pharma has a market cap or net worth of INR 291.99 billion. The enterprise value is 267.05 billion.
| Market Cap | 291.99B |
| Enterprise Value | 267.05B |
Important Dates
The next estimated earnings date is Monday, February 3, 2025.
| Earnings Date | Feb 3, 2025 |
| Ex-Dividend Date | Aug 16, 2024 |
Share Statistics
| Current Share Class | n/a |
| Shares Outstanding | n/a |
| Shares Change (YoY) | +0.00% |
| Shares Change (QoQ) | +0.01% |
| Owned by Insiders (%) | n/a |
| Owned by Institutions (%) | n/a |
| Float | 73.17M |
Valuation Ratios
The trailing PE ratio is 42.22.
| PE Ratio | 42.22 |
| Forward PE | n/a |
| PS Ratio | n/a |
| PB Ratio | n/a |
| P/TBV Ratio | 3.47 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 20.92, with an EV/FCF ratio of 32.09.
| EV / Earnings | 38.62 |
| EV / Sales | 4.53 |
| EV / EBITDA | 20.92 |
| EV / EBIT | 29.91 |
| EV / FCF | 32.09 |
Financial Position
The company has a current ratio of 4.16, with a Debt / Equity ratio of 0.04.
| Current Ratio | 4.16 |
| Quick Ratio | 2.80 |
| Debt / Equity | 0.04 |
| Debt / EBITDA | 0.26 |
| Debt / FCF | 0.39 |
| Interest Coverage | 39.58 |
Financial Efficiency
Return on equity (ROE) is 8.09% and return on invested capital (ROIC) is 6.28%.
| Return on Equity (ROE) | 8.09% |
| Return on Assets (ROA) | 5.27% |
| Return on Capital (ROIC) | 6.28% |
| Revenue Per Employee | 13.97M |
| Profits Per Employee | 1.64M |
| Employee Count | 4,217 |
| Asset Turnover | 0.56 |
| Inventory Turnover | 1.48 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -4.23% in the last 52 weeks.
| Beta (5Y) | n/a |
| 52-Week Price Change | -4.23% |
| 50-Day Moving Average | 1,729.68 |
| 200-Day Moving Average | 1,817.86 |
| Relative Strength Index (RSI) | 51.15 |
| Average Volume (20 Days) | 8,022 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Gland Pharma had revenue of INR 58.90 billion and earned 6.92 billion in profits. Earnings per share was 41.98.
| Revenue | 58.90B |
| Gross Profit | 31.87B |
| Operating Income | 8.93B |
| Pretax Income | 10.56B |
| Net Income | 6.92B |
| EBITDA | 12.57B |
| EBIT | 8.93B |
| Earnings Per Share (EPS) | 41.98 |
Balance Sheet
The company has 28.20 billion in cash and 3.27 billion in debt, giving a net cash position of 24.93 billion.
| Cash & Cash Equivalents | 28.20B |
| Total Debt | 3.27B |
| Net Cash | 24.93B |
| Net Cash Per Share | n/a |
| Equity (Book Value) | 87.88B |
| Book Value Per Share | 533.63 |
| Working Capital | 48.65B |
Cash Flow
In the last 12 months, operating cash flow was 12.19 billion and capital expenditures -3.86 billion, giving a free cash flow of 8.32 billion.
| Operating Cash Flow | 12.19B |
| Capital Expenditures | -3.86B |
| Free Cash Flow | 8.32B |
| FCF Per Share | n/a |
Margins
Gross margin is 54.11%, with operating and profit margins of 15.16% and 11.74%.
| Gross Margin | 54.11% |
| Operating Margin | 15.16% |
| Pretax Margin | 17.94% |
| Profit Margin | 11.74% |
| EBITDA Margin | 21.35% |
| EBIT Margin | 15.16% |
| FCF Margin | 14.13% |
Dividends & Yields
Gland Pharma does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | 47.65% |
| Buyback Yield | -0.00% |
| Shareholder Yield | -0.00% |
| Earnings Yield | 2.37% |
| FCF Yield | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | n/a |